Soluble fms-like tyrosine kinase-1 and atherosclerosis in chronic kidney disease

9Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Vascular endothelial growth factor (VEGF) and its cousins, such as placental growth factor, have moved into the daily clinical arena. One-step-removed regulators, such as the VEGF splice variant soluble fms-like tyrosine kinase-1 (sFlt-1), now clinically emerge. sFlt-1 keeps our corneas 'clean.' However, sFlt-1 could also cause disease, such as preeclampsia. The report by Matsui et al. on ApoE and sFlt-1 gene-deleted mice could foster important subsequent research. We are limited only by our imaginations. © 2013 International Society of Nephrology.

Cite

CITATION STYLE

APA

Luft, F. C. (2014). Soluble fms-like tyrosine kinase-1 and atherosclerosis in chronic kidney disease. Kidney International. Nature Publishing Group. https://doi.org/10.1038/ki.2013.402

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free